The FDA issued a clinical hold on an early-stage trial for Unum Therapeutics' ACTR087, in combination with Roche's Rituxan, or rituximab, which are being evaluated as a treatment for patients with relapsed or refractory CD20-positive B cell non-Hodgkin lymphoma after treatment with lymphodepleting chemotherapy. The hold followed a report of major neurotoxicity, cytomegalovirus infection and life-endangering respiratory distress in a patient enrolled in the study.
Clinical hold issued for Unum's non-Hodgkin lymphoma drug
Sign up for FDLI SmartBrief
News for the food and drug law community
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.